Possible contribution of XYY syndrome to neuroleptic malignant syndrome in a child receiving quetiapine

American Journal of Health-System Pharmacy

Volumn 67, Issue 6, 2010, Pages 459-461

  Randolph, Timothy C ^a  

^a CAROLINAS MEDICAL CENTER   (United States)

Author keywords

Antipsychotic agents; Attention deficit and disruptive behavior disorders; Chromosome aberrations; Neuroleptic malignant syndrome; Pediatrics; Quetiapine; Toxicity

Indexed keywords

CLONIDINE; CREATINE KINASE; CREATINE KINASE MB; CREATINE KINASE MM; QUETIAPINE;

AGITATION; ARTICLE; ATAXIA; BEDTIME DOSAGE; CASE REPORT; CHILD; CLINICAL EVALUATION; CONFUSION; CREATINE KINASE BLOOD LEVEL; DIAPHORESIS; DISEASE SEVERITY; DRUG MEGADOSE; DRUG WITHDRAWAL; EMERGENCY CARE; GAIT DISORDER; HOSPITAL DISCHARGE; HUMAN; KARYOTYPE 47,XYY; MALE; MOOD DISORDER; MUSCLE INJURY; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; OPPOSITIONAL DEFIANT DISORDER; PRESCHOOL CHILD; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SOMNOLENCE; TREATMENT DURATION;

EID: 77949581860     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp090091     Document Type: Article

References (14)

1. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/ hyperactivity disorder. Arch Gen Psychiatry. 1999;56:1073-86.
2. Diagnostic and statistical manual of mental disorders. 4th ed. Rev. Washington, DC: American Psychiatric Association; 1994.
3. Seroquel (quetiapine) package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2001.
4. Fryns JP, Kleczkowska A, Kubien E et al. XYY syndrome and other Y chromosome polysomies. Mental status and psychosocial functioning. Genet Couns. 1995; 6:197-206.
5. Jacobs PA, Brunton M, Melville MM et al. Aggressive behavior, mental subnormality and the XYY male. Nature. 1965;208:1351-2.
6. Shibata S, Kami M, Kishi Y et al. Severe regimen-related toxicity occurring in a patient with XYY syndrome receiving allogenic peripheral blood stem cell transplantation. Ann Hematol. 2002;81:407-9.
7. Gambassi G, Capurso S, Tarsitani P et al. Fatal neuroleptic malignant syndrome in a previously long-term user of clozapine following its reintroduction in combination with paroxetine. Aging Clin Exp Res. 2006;18:266-70.
8. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993;77:185-202.
9. Bhanushali MJ, Tuite PJ. The evaluation and management of patients with neuroleptic malignant syndrome. Neurol Clin. 2004;22:389-411.
10. Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry. 2008; 69(suppl4):26-36.
11. Susman VL. Clinical management of neuroleptic malignant syndrome. Psychiatr Q. 2001;72:325-36.
12. Duggal HS. Possible neuroleptic malignant syndrome associated with palperidone. J Neuropsychiatry Clin Neurosci. 2007;19:477-8.
13. Croarkin PE, Emslie GJ, Mayes TL. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. J Clin Psychiatry. 2008;69:1157-65.
14. Martin A, Koenig K, Scahill L et al. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol. 1999;9:999-1007.